NCT07600515Not yet recruiting
Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy. Emerging evidence suggests that HPV clearance is linked to better outcomes and that HPV testing may outperform cytology in detecting recurrence. This study aims to evaluate a panel of prognostic biomarkers to identify patients at higher risk of recurrence. These include cervical and circulating HPV-DNA (presence, genotype, and load), vaginal microbiota, host DNA methylation, SOD2 expression, and immune profile. By enabling earlier and more accurate detection of recurrence, these biomarkers may improve patient outcomes, reduce reliance on costly imaging, and support earlier discharge for low-risk patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 14 May 2026
- Start date
- 10 May 2026
- Primary completion date
- 10 May 2029
- Lead sponsor
- Instituto do Cancer do Estado de São Paulo
- Diseases
- Cervical cancer
- NCT number
- NCT07600515
What you commit to
- Study type: Observational
- Planned participants: 100
- From 10 May 2026 to the primary completion date, 10 May 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned initial treatment is surgical or palliative
Other illness
- Immunosuppression (e.g., HIV infection with active disease, autoimmune diseases, transplant recipients)
Other
- Tumors with rare histology, such as small cell tumors, sarcomas, and lymphomas
- FIGO 2018 stages IA, IB1, IB2, and IVB
- Uncertain primary tumor site (cervix vs. endometrium)
- Pregnant or in the postpartum period
Who the study is looking for
- Diagnosis of HPV-associated squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Treatment-naïve
- FIGO 2018 stage IB3 to IVA
- Candidates for curative-intent pelvic radiotherapy with concurrent chemoradiation
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.